Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Abstract Background Acromegaly is a rare, chronic and severe disease. Drug therapy including somatostatin analogues (SAs), dopamine receptor agonists and growth hormone receptor antagonists (pegvisomant, PEG) are commonly used to treat patients who do not respond to surgery. The use of combination t...
Main Authors: | Lingyun Ma, Daohuang Luo, Ting Yang, Songtao Wu, Min Li, Chaoyang Chen, Shuang Zhou, Lingyue Ma, Ye Wu, Ying Zhou, Yimin Cui |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | BMC Endocrine Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12902-020-0545-2 |
Similar Items
-
The position of combined medical treatment in acromegaly
by: Eva C. Coopmans, et al.
Published: (2020-01-01) -
Management of persistent acromegaly following primary therapy: The current landscape in the UK
by: Nikolaos Kyriakakis, et al.
Published: (2020-07-01) -
Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)
by: Larisa K. Dzeranova, et al.
Published: (2019-12-01) -
CURRENT VIEWS ON THE TREATMENT OF ACROMEGALY WITH SOMATOSTATIN ANALOGUES
by: I. A. Ilovaiskaya
Published: (2017-12-01) -
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
by: Sang Ouk Chin, et al.
Published: (2019-03-01)